198 related articles for article (PubMed ID: 36715558)
1. Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study.
Barr CE; Sergeant JC; Agnew HJ; Bolton J; McVey RJ; Crosbie EJ
BJOG; 2023 Jul; 130(8):941-948. PubMed ID: 36715558
[TBL] [Abstract][Full Text] [Related]
2. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.
Mandelbaum RS; Ciccone MA; Nusbaum DJ; Khoshchehreh M; Purswani H; Morocco EB; Smith MB; Matsuzaki S; Dancz CE; Ozel B; Roman LD; Paulson RJ; Matsuo K
Am J Obstet Gynecol; 2020 Jul; 223(1):103.e1-103.e13. PubMed ID: 31978437
[TBL] [Abstract][Full Text] [Related]
3. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
[TBL] [Abstract][Full Text] [Related]
4. Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer.
Behrouzi R; Ryan NAJ; Barr CE; Derbyshire AE; Wan YL; Maskell Z; Stocking K; Pemberton PW; Bolton J; McVey RJ; Crosbie EJ
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31979212
[TBL] [Abstract][Full Text] [Related]
5. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract][Full Text] [Related]
6. Weight Loss During Intrauterine Progestin Treatment for Obesity-associated Atypical Hyperplasia and Early-Stage Cancer of The Endometrium.
Barr CE; Ryan NAJ; Derbyshire AE; Wan YL; MacKintosh ML; McVey RJ; Bolton J; Fitzgerald C; Awad D; Slade RJ; Syed AA; Ammori BJ; Crosbie EJ
Cancer Prev Res (Phila); 2021 Nov; 14(11):1041-1050. PubMed ID: 34348914
[TBL] [Abstract][Full Text] [Related]
7. HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.
Ørbo A; Arnes M; Lyså LM; Borgfeldt C; Straume B
Br J Cancer; 2016 Sep; 115(6):725-30. PubMed ID: 27537387
[TBL] [Abstract][Full Text] [Related]
8. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.
Pronin SM; Novikova OV; Andreeva JY; Novikova EG
Int J Gynecol Cancer; 2015 Jul; 25(6):1010-4. PubMed ID: 25950126
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.
Pal N; Broaddus RR; Urbauer DL; Balakrishnan N; Milbourne A; Schmeler KM; Meyer LA; Soliman PT; Lu KH; Ramirez PT; Ramondetta L; Bodurka DC; Westin SN
Obstet Gynecol; 2018 Jan; 131(1):109-116. PubMed ID: 29215513
[TBL] [Abstract][Full Text] [Related]
10. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.
Orbo A; Vereide A; Arnes M; Pettersen I; Straume B
BJOG; 2014 Mar; 121(4):477-86. PubMed ID: 24286192
[TBL] [Abstract][Full Text] [Related]
11. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
[TBL] [Abstract][Full Text] [Related]
12. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
[TBL] [Abstract][Full Text] [Related]
13. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
[TBL] [Abstract][Full Text] [Related]
14. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
[TBL] [Abstract][Full Text] [Related]
15. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy.
Gallos ID; Ganesan R; Gupta JK
Obstet Gynecol; 2013 Jun; 121(6):1165-1171. PubMed ID: 23812448
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.
Ciccone MA; Whitman SA; Conturie CL; Brown N; Dancz CE; Özel B; Matsuo K
Arch Gynecol Obstet; 2019 Mar; 299(3):801-808. PubMed ID: 30706187
[TBL] [Abstract][Full Text] [Related]
17. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
18. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
[TBL] [Abstract][Full Text] [Related]
19. Predictive Accuracy of Progesterone Receptor B in Young Women with Atypical Endometrial Hyperplasia and Early Endometrial Cancer Treated with Hysteroscopic Resection plus LNG-IUD Insertion.
Raffone A; Travaglino A; Zullo FM; Gencarelli A; Micheli M; Miranda S; De Franciscis P; Insabato L; Di Spiezio Sardo A; Zullo F; Bifulco G
J Minim Invasive Gynecol; 2021 Jun; 28(6):1244-1253. PubMed ID: 33122144
[TBL] [Abstract][Full Text] [Related]
20. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Dominick S; Hickey M; Chin J; Su HI
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
